Pressemitteilung BoxID: 581979 (4SC AG)
  • 4SC AG
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • Ansprechpartner
  • Chad Rubin
  • +1 (646) 378-2947

4SC to host conference call and webcast on 25 March 2013 to present full year financial results for 2012

(PresseBox) (Planegg-Martinsried, ) 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, will announce results of the 4SC Group for the year 2012 and publish the company's Annual Report 2012 on 25 March 2013. On this day the Management Board of 4SC AG will host a conference call at 3pm CET (10am US EST) to inform about the consolidated financial statements 2012 and provide further details on the company's latest developments.

Investors, financial analysts, and journalists participating in the conference call may have live access to the presentation slides at (Login: 4sc0313) and can access the conference using the following telephone numbers:

Date: 25 March 2013
Time: 3pm CET (10am US EST)
Dial-in numbers: +49-6958-999-0806 (Germany)
+44-207-153-2027 (UK)
+1-480-629-9822 (USA)
+49-6958-999-0806 (other countries)

Conference-ID: 4608496

Access to the complete webcast, including presentation slides and voice stream, can be obtained from 3pm CET (10am US EST) at: A replay of the webcast and the conference call will also be available at the "investors" section of the website

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

For more information please visit


The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC had 86 employees at the end of 2012. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.